APA (7th ed.) Citation

García, C., Gómez-Cañas, M., Burgaz, S., Palomares, B., Gómez-Gálvez, Y., Palomo-Garo, C., . . . Fernández-Ruiz, J. (2018). Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: Possible involvement of different binding sites at the PPARγ receptor. BMC.

Chicago Style (17th ed.) Citation

García, Concepción, et al. Benefits of VCE-003.2, a Cannabigerol Quinone Derivative, Against Inflammation-driven Neuronal Deterioration in Experimental Parkinson’s Disease: Possible Involvement of Different Binding Sites at the PPARγ Receptor. BMC, 2018.

MLA (9th ed.) Citation

García, Concepción, et al. Benefits of VCE-003.2, a Cannabigerol Quinone Derivative, Against Inflammation-driven Neuronal Deterioration in Experimental Parkinson’s Disease: Possible Involvement of Different Binding Sites at the PPARγ Receptor. BMC, 2018.